19/12/2023
Big news in the medical world! 🌐🧬 The revolutionary gene-editing technology, CRISPR, has made a massive leap from the lab to the clinic with the FDA's approval of the first CRISPR treatment for sickle cell disease ✅
Introducing exa-cel, a collaboration between Vertex and CRISPR Therapeutics, that's changing the game in genetic disorders. 🔬 This groundbreaking treatment edits a key gene in red blood cells, potentially offering a functional cure for sickle cell disease patients for at least a year! 🩸
The U.S. joins the U.K. in embracing this scientific milestone, marking a new chapter in healthcare. 🇺🇸🇬🇧 While it's still early days to predict long-term outcomes and side effects, the potential is enormous, as noted by hematologist Michael DeBaun from Vanderbilt University. 🏥
Also in the spotlight is lovo-cel by bluebird bio, another gene therapy approved by the FDA for sickle cell disease. 🌟 Exa-cel's Cas9 enzyme targets and deactivates the BCL11A gene, allowing the production of fetal hemoglobin and normal-shaped red blood cells. 🧬🔁
This isn't just a treatment; it's a step towards a cure. With cells edited by exa-cel repopulating the body, the therapy promises a lasting impact. Though trials are still in the early stages, the future looks promising for those affected by sickle cell anemia and beta-thalassemia. 🌅
Ref https://www.scientificamerican.com/article/fda-approves-first-crispr-gene-editing-treatment-for-sickle-cell-disease
